Post-Marketing Requirement Study to Evaluate the Safety of Octaplas Versus Plasma in Patients Undergoing Orthotopic Liver Transplantation With Special Emphasis on Hyperfibrinolysis.
Phase of Trial: Phase IV
Latest Information Update: 04 Oct 2017
At a glance
- Drugs Plasma (Primary)
- Indications Haemorrhage
- Focus Adverse reactions
- Sponsors Octapharma
- 12 Aug 2016 Planned End Date changed from 1 May 2017 to 1 Dec 2019.
- 12 Aug 2016 Planned primary completion date changed from 1 Feb 2017 to 1 Dec 2019.
- 25 Aug 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.